Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4947779 | 0.89 | SCN9A (0.47) | SCN9ASCN5AGRM5MAP4K4 | |
| SCHEMBL4950919 | 0.84 | PTGS1 (0.45) | GRM5PTGS1 | |
| SCHEMBL5141284 | 0.82 | SCN9A (0.47) | SCN9ASCN5AGRM5MAP4K4 | |
| SCHEMBL4953416 | 0.78 | MEN1 (0.40) | PTGS1 | |
| SCHEMBL4948364 | 0.78 | ESR2 (0.40) | PTGS1 | |
| SCHEMBL4948323 | 0.78 | STS (0.48) | PTGS1 | |
| SCHEMBL4950450 | 0.77 | PTGS1 (0.50) | PTGS1 | |
| SCHEMBL4951183 | 0.77 | DGAT1 (0.37) | PTGS1 | |
| SCHEMBL4950102 | 0.74 | PTGS1 (0.41) | SCN9ASCN5AGRM5MAP4K4PTGS1 | |
| SCHEMBL4948155 | 0.74 | ESR2 (0.50) | PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893597-B1 | AMPA RECEPTOR POTENTIATORS | LILLY CO ELI (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7393868-B2 | AMPA receptor potentiators | ELI LILLY AND COMPANY (US) | 2008-07-01 | — | — | US | disclosed |
| US-20070142441-A1 | AMPA receptor potentiators | ELI LILLY AND COMPANY | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142441-A1 | AMPA receptor potentiators | GABRE, GRIN1, GRIK2 | SCN9A 466/4885SCN5A 666/4885GRM5 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.